Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ortho's levofloxacin

Executive Summary

Included in treatment regimen of a National Institute of Allergy & Infectious Diseases nationwide clinical trial for persons co- infected with HIV and tuberculosis. The fluoroquinolone is being developed by Ortho in the U.S. under license from Daichii in Japan. The 650-person open-label trial (CPCRA 019/ACTG 222) will evaluate in an induction phase the addition of levofloxacin to the standard treatment regimen of isoniazid (INH supplied by Danbury Pharmacal), vitamin B6, administered with INH (Tishcon Corp.), rifampin (Marion Merrell Dow), ethambutol and pyrazinamide (Lederle) in people with drug-resistant TB, as well as in variations on the drug treatment regimen during the trial's continuation phase. NIAID hopes a shorter treatment regimen or an effective intermittent regimen would increase therapy compliance.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022440

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel